Efficacy of sandostatin LAR in type 1 DM; improvement in glycemic control with less insulin. a case report
James Bonucchi, Kathy Lilli, Udaya Kabadi
DOI: 10.4236/jdm.2011.11003   PDF   HTML     3,767 Downloads   6,846 Views  


Objective: Octreotide three times daily is re-ported to reduce daily insulin by 50% in patients with Type 1 DM. Therefore, we assessed the impact of long acting Octreotide (Sandostatin LAR) monthly Intramuscular administration in a subject with Type 1 DM. Methods: A 32-year-old man with Type 1 DM of 16 years participated after obtaining informed consent. He had no microvascular or macrovascular complications. He continued the present insulin regimen for four weeks. IM Sandostatin LAR 20 mg was initiated and increased at four weeks to 30 mg. He was followed every four weeks for six months. Insulin regimen was adjusted every two weeks based on blood glucose before meals, bedtime and on onset of hypoglycemic symptoms. He continued other medications, previous diet and activity Assessment of HbA1c, serum electrolytes, urea nitrogen, creatinine, TSH, free T4, liver enzymes, complete blood cell counts, vitamin B12, lipids and insulin regimen were performed at the initiation and end of the study. Results: HbA1c declined from 9 to 8% with reduction in daily insulin dose from 55 to 43 units, with a major reduction in insulin Glargine, 50 to 40 units. Body weight remained unaltered. Other laboratory tests including gallbladder examina-tion remained unchanged Conclusion: Monthly Sandostatin LAR administration may improve glycemic control with less insulin in Type 1 DM.

Share and Cite:

Bonucchi, J. , Lilli, K. and Kabadi, U. (2011) Efficacy of sandostatin LAR in type 1 DM; improvement in glycemic control with less insulin. a case report. Journal of Diabetes Mellitus, 1, 15-16. doi: 10.4236/jdm.2011.11003.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Dimitradis, G., et al. (1983) Effects of long acting somatostatin analogue on post-prandial hyperglycemia in insulin-dependent diabetes mellitus. Metabolism 32, 987- 992. doi:10.1016/0026-0495(83)90140-3
[2] Spinas, G.A., et al. (1985) .Reduced post-prandial hyperglycemia after subcutaneous injection of a somatostatin- analogue (SMS 201-995) in insulin dependent diabetes mellitus. Diabetes Care, 8, 429-435. doi:10.2337/diacare.8.5.429
[3] Rios, M.S., Navascues, I., Saban, J., Ordonez, A., Sevilla, F. and Del Pozo, E. (1986) Somatostatin analog SMS 201-995 and insulin needs in insulin-dependent diabetic patients studied by means of an artificial pancreas. The Journal of Clinical Endocrinology & Metabolism, 63, 1071-1074.
[4] Grossman, L.D., Shumak, S.L., George, S.R., Singer, W. and Zinman, B. (1989) The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. The Journal of Clinical Endocrinology & Metabolism, 68, 63-70. doi:10.1210/jcem-68-1-63
[5] Ludwigsen, E., Stridsberg, M., Taylor, J.E., Cutler, M.D., Oberg, K., Janson, E.T. and Standler S. (2007) Regulation of insulin and glucagon secretion from rat pancreatic islets in vitro by somatostatin analogues. Regulatory Peptides, 138, 1-9. doi:10.1016/j.regpep.2006.07.006
[6] Singh, V., Brenel, M.D., Zacharias, S., Mergler, S., Jahr, H., Wiedemnan, B., Bretzel, R.G., Plockinger, U., and Strowski, M.Z., (2007) Charecterization of soamtostatin receptor subtype-specific regulation of insulin and glucagon secretion: An in vitro study on isolated human pancreas. The Journal of Clinical Endocrinology & Metabolism, 92, 673-680. doi:10.1210/jc.2006-1578
[7] Brazeau, P., Vale, W. and Burgus, R. (1973) Hypothalamic Polypeptide that Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone. Science, 179, 77-83. doi:10.1126/science.179.4068.77
[8] Fery, F., Tappy, L., Schneiter, P., Daviere, J.E. and Balasse, O. (2005) Effect of Somatostatin on Duodenal Glucose Absorption in Man. The Journal of Clinical Endocrinology & Metabolism, 90, 4163-4169. doi:10.1210/jc.2004-1766
[9] Manjila, S., Wu, O.C., Khan, F.R., Khan, M.M., Arafah, B.M. and Setman, W.R. (2010) Pharmacological management of acromegaly: A current perspective. Neurosurgical Focus, 29, E14-24. doi:10.3171/2010.7.FOCUS10168
[10] Corleto, V.D. (2010) Somatostatin and the gastrointestinal tract. Current Opinion in Endocrinology, Diabetes & Obesity, 17, 63-68.

Copyright © 2022 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.